Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects

Drug Metabolism and Disposition

Volumn 31, Issue 9, 2003, Pages 1142-1150

  Lantz, R J ^a   Gillespie, T A ^a   Rash, T J ^a   Kuo, F ^a   Skinner, M ^b   Kuan, H Y ^a,c   Knadler, Mary Pat ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYDULOXETINE; 4,6 DIHYDROXYDULOXETINE; 6 HYDROXY 5 METHOXYDULOXETINE; DULOXETINE; NORADRENALIN; SEROTONIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOTRANSFORMATION; CLINICAL TRIAL; DEPRESSION; DRUG CONJUGATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; ENTERIC COATED TABLET; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; SWEATING; URINARY EXCRETION; URINE INCONTINENCE; VOMITING;

ADMINISTRATION, ORAL; ADRENERGIC UPTAKE INHIBITORS; ADULT; AREA UNDER CURVE; BREATH TESTS; FECES; FEMALE; HALF-LIFE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MIDDLE AGED; OXIDATION-REDUCTION; SEROTONIN UPTAKE INHIBITORS; TABLETS, ENTERIC-COATED; THIOPHENES; TIME FACTORS;

EID: 0041856533     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.9.1142     Document Type: Article

References (12)

1. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, and Demitrack MA (2002) Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 63:308-315.
2. Goldstein DJ, Mallinckrodt C, Lu Y, and Demitrack MA (2002) Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 63:225-231.
3. Norton PA, Zinner NR, Yalcin I, and Bump RC (2002) Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 187:40-48.
4. Pitsikas N (2000) Duloxetine Eli Lilly and Co. Curr Opin Investig Drugs 1:116-121.
5. Rueter LE, DeMontigny C, and Blier P (1998) Electrophysiological characterization of the effect of long-term duloxetine administration on the rat serotonergic and noradrenergic systems. J Pharmacol Exp Ther 285:404-412.
6. Sharma A, Goldberg MJ, and Cerimele BJ (2000) Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 40:161-167.
7. Skinner MH, Kuan HY, Pan A, Sathirakul K, Knadler MP, Gonzales CR, Yeo KP, Reddy S, Lim M, Ayan-Oshodi M, and Wise SD (2003) Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 73:170-177.
8. Thor KB and Katofiasc MA (1995) Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 274:1014-1024.
9. Wheeler WJ and Kuo F (1995) An asymmetric synthesis of duloxetine hydrochloride, a mixed uptake inhibitor of serotonin and norepinephrine and its C-14 labeled isotopomers. J Labelled Compd Radiopharm 36:213-223.
10. Wong DT (1998) Duloxetine (LY248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate. Exp Opin Investig Drugs 7:1-9.
11. Wong DT and Bymaster FP (2002) Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res 58:169-222.
12. Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, and Robertson DW (1993) LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 8:23-33.